Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.39 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2494142 | 0.82 | SLC6A3 (0.40) | SLC6A3SLC6A4SLC6A2CXCR5AVPR1A | |
| SCHEMBL2899070 | 0.77 | AKR1C1 (0.47) | SLC6A3SLC6A4SLC6A2LMNAAKR1C1 | |
| Benzene SCHEMBL27670886 | 0.77 | AKR1C1 (0.47) | SLC6A3SLC6A4SLC6A2LMNAAKR1C1 | |
| SCHEMBL20446611 | 0.75 | SLC6A3 (0.40) | SLC6A3SLC6A4SLC6A2LMNAPOLB | |
| SCHEMBL8112531 | 0.73 | AKR1C1 (0.52) | SLC6A3SLC6A4SLC6A2CXCR5NR4A1 | |
| SCHEMBL697151 | 0.72 | AKR1C1 (0.48) | SLC6A3SLC6A4SLC6A2CXCR5NR4A1 | |
| SCHEMBL21722268 | 0.67 | SLC6A4 (0.43) | SLC6A3SLC6A4SLC6A2CXCR5LMNA | |
| SCHEMBL11014788 | 0.67 | SLC6A3 (0.40) | SLC6A3SLC6A4SLC6A2CXCR5NR4A1 | |
| SCHEMBL6231574 | 0.66 | SLC6A3 (0.44) | SLC6A3SLC6A4SLC6A2AVPR1AKDM4E | |
| SCHEMBL8106448 | 0.66 | SLC6A3 (0.45) | SLC6A3SLC6A4SLC6A2NR4A1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964601-B2 | Agonist or antgonist and binders and inversion of agonist | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7732451-B2 | Naphthalene-containing melanocortin receptor-specific small molecule | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7718802-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7709484-B1 | Substituted melanocortin receptor-specific piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7655658-B2 | Use of in the treatment of melanocortin receptor-associated disorders such as in treatment of anorexia, as a weight gain aid, for treatment of obesity | PALATIN TECHNOLOGIES, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| WO-2009144432-A1 | MC4-R AGONISTS FOR THE TREATMENT OF OBESITY | PALATIN TECHNOLOGIES, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| US-7601753-B2 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090253713-A1 | Small Molecule Compositions for Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-7550602-B1 | Small molecule compositions for sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090076029-A1 | Compounds and Methods for Treating Obesity | PALATIN TECHNOLOGIES, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20070155670-A1 | Pyrrolidine Melanocortin-Specific Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7189755-B2 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1622618-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | Palatin Technologies, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005102340-A1 | PIPERAZINE MELANOCORTIN-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| US-20050130988-A1 | Naphthalene-containing melanocortin receptor-specific small molecule | PALATIN TECHNOLOGIES, INC. (US) | 2005-06-16 | — | — | US | disclosed |
| US-20050124636-A1 | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2004098602-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040167201-A1 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-26 | — | — | US | disclosed |
| US-20040157264-A1 | Piperazine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130988-A1 | Naphthalene-containing melanocortin receptor-specific small molecule | MC1R, MC3R, MC2R | SLC6A3 529/4885SLC6A4 980/4885SLC6A2 357/4885 |
| US-20040167201-A1 | Pyrrolidine melanocortin-specific compounds | MC3R, MC1R, MC5R | SLC6A3 123/4885SLC6A4 310/4885SLC6A2 262/4885 |
| US-20040157264-A1 | Piperazine melanocortin-specific compounds | MC1R, MC5R, MC3R | SLC6A3 246/4885SLC6A4 507/4885SLC6A2 425/4885 |
| US-20090076029-A1 | Compounds and Methods for Treating Obesity | MC4R, MC3R, MC1R | SLC6A3 349/4885SLC6A4 463/4885SLC6A2 449/4885 |
| US-20070155670-A1 | Pyrrolidine Melanocortin-Specific Compounds | MC3R, MC1R, MC5R | SLC6A3 108/4885SLC6A4 204/4885SLC6A2 205/4885 |
| US-20090253713-A1 | Small Molecule Compositions for Sexual Dysfunction | PDE3B, PDE3A, PDE5A | SLC6A3 94/4885SLC6A4 393/4885SLC6A2 153/4885 |
| US-20050124636-A1 | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds | MC1R, MC5R, MC4R | SLC6A3 236/4885SLC6A4 374/4885SLC6A2 304/4885 |
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | MC3R, MC4R, MC1R | SLC6A3 526/4885SLC6A4 570/4885SLC6A2 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.